Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
1645 participants
INTERVENTIONAL
2017-11-05
2019-10-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Wild poliovirus type 2 (WPV2) was declared eradicated in September 2015. Since then paralysis associated with type 2 poliovirus has continued mainly due to vaccine derived polio viruses (VDPVs) from type 2 OPV (OPV2). Due to the continued threat of paralysis from a mutated, neurovirulent and vaccine-derived type 2 poliovirus, the Strategic Advisory Group of Experts on Immunization (SAGE), a global advisory committee on immunization, recommended a phased cessation of OPV starting with OPV2. By May 2016, OPV2 was successfully withdrawn globally when trivalent OPV (tOPV) was replaced with bivalent OPV (bOPV), which was preceded by a phased introduction of inactivated poliovirus vaccine (IPV). SAGE has recommended at least one dose of IPV at age ≥14 weeks because IPV immunogenicity is expected to be highest after maternal antibodies have declined by age 14 weeks. However, studies have not assessed if priming after one IPV dose declines over time.
Types 1 and 3 OPV cessation is likely expected in 2020-2022, i.e. 1-2 years after certification of global interruption of wild poliovirus transmission. After cessation of bOPV, IPV will be used for routine polio vaccination for 5-10 years.Recently, SAGE recommended that IPV be used after global OPV withdrawal with an IPV schedule that achieves at least 90% seroconversion with two full or fractional doses. SAGE has recommended that the first dose be administered after 14 weeks of age and an interval of at least 4 months between two IPV doses. In the proposed clinical trial, immunogenicity of two IPV doses with schedules that are likely to achieve 90% immune response to all poliovirus types is being assessed to inform SAGE policy deliberations on potential IPV schedules after OPV cessation. A head-to-head comparison of different IPV schedules is important to determine the immunogenicity of the schedules under similar conditions and evaluate the differences in population immunity, a product of immunogenicity and vaccination coverage, with the different IPV schedules.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
IPV at ages 14 weeks and 18 months
Participants in this arm will receive bivalent oral poliovirus vaccine (bOPV) at 6, 10 and 14 weeks of age and inactivated poliovirus vaccine (IPV) at 14 weeks and 18 months of age
Bivalent oral poliovirus vaccine (bOPV) at 6,10 and 14 weeks of age
bOPV at 6, 10 and 14 weeks of age
Inactivated poliovirus vaccine (IPV) at 14 weeks and 18 months of age
IPV at 14 weeks and 18 months of age
IPV at ages 14 weeks, 18 weeks and 18 months
Participants in this arm will receive bivalent oral poliovirus vaccine (bOPV) at 6, 10 and 14 weeks of age and inactivated poliovirus vaccine (IPV) at 14 weeks, 18 weeks and 18 months of age
Bivalent oral poliovirus vaccine (bOPV) at 6,10 and 14 weeks of age
bOPV at 6, 10 and 14 weeks of age
Inactivated poliovirus vaccine (IPV) at 14 weeks, 18 weeks and 18 months of age
IPV at 14 weeks, 18 weeks and 18 months of age
IPV at ages 14 weeks and 9 months
Participants in this arm will inactivated poliovirus vaccine (IPV) at 14 weeks and 9 months of age
Inactivated poliovirus vaccine (IPV) at 14 weeks and 9 months of age
IPV at 14 weeks and 9 months of age
IPV at ages 6 weeks and 9 months
Participants in this arm will inactivated poliovirus vaccine (IPV) at 6 weeks and 9 months of age
Inactivated poliovirus vaccine (IPV) at 6 weeks and 9 months of age
IPV at 6 weeks and 9 months of age
IPV at ages 6 and 14 weeks
Participants in this arm will inactivated poliovirus vaccine (IPV) at 6 and 14 weeks of age
Inactivated poliovirus vaccine (IPV) at 6 and 14 weeks of age
IPV at 6 and 14 weeks of age
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bivalent oral poliovirus vaccine (bOPV) at 6,10 and 14 weeks of age
bOPV at 6, 10 and 14 weeks of age
Inactivated poliovirus vaccine (IPV) at 14 weeks and 18 months of age
IPV at 14 weeks and 18 months of age
Inactivated poliovirus vaccine (IPV) at 14 weeks, 18 weeks and 18 months of age
IPV at 14 weeks, 18 weeks and 18 months of age
Inactivated poliovirus vaccine (IPV) at 14 weeks and 9 months of age
IPV at 14 weeks and 9 months of age
Inactivated poliovirus vaccine (IPV) at 6 weeks and 9 months of age
IPV at 6 weeks and 9 months of age
Inactivated poliovirus vaccine (IPV) at 6 and 14 weeks of age
IPV at 6 and 14 weeks of age
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Parents that consent for participation in the full length of the study.
* Parents that are able to understand and comply with planned study procedures.
Exclusion Criteria
* A diagnosis or suspicion of immunodeficiency disorder either in the infant or in an immediate family member.
* A diagnosis or suspicion of bleeding disorder that would contraindicate parenteral administration of IPV or collection of blood by venipuncture.
* Acute diarrhoea, infection or illness at the time of enrollment (6 weeks of age) that would require infant's admission to a hospital.
* Acute vomiting and intolerance to liquids within 24 hours before the enrollment visit (6 weeks of age).
* Evidence of a chronic medical condition identified by a study medical officer during physical exam.
* Receipt of any polio vaccine (OPV or IPV) before enrollment based upon documentation or parental recall.
* Known allergy/sensitivity or reaction to polio vaccine, or its contents.
* Infants from multiple births. Infants from multiple births will be excluded because the infant(s) who is/are not enrolled would likely receive OPV through routine immunization and transmit vaccine poliovirus to the enrolled infant.
* Infants from premature births (\<37 weeks of gestation).
6 Weeks
7 Weeks
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
International Centre for Diarrhoeal Disease Research, Bangladesh
OTHER
Centers for Disease Control and Prevention
FED
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
International Center for Diarrhoeal Disease Research, Bangladesh
Dhaka, , Bangladesh
Mirpur clinic (International Center for Diarrhoeal Disease Research, Bangladesh)
Dhaka, , Bangladesh
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ICDDRB-RRC-PR-17034
Identifier Type: -
Identifier Source: org_study_id